Susceptibility Testing on a Biofilm-Associated Wound Infection
A 6-year-old dog has a chronic, non-healing wound on the lateral thigh after a dog bite 5 weeks ago. The wound is malodorous with a thick biofilm and surrounding erythema. A deep tissue sample grows Pseudomonas aeruginosa and Staphylococcus pseudintermedius. Routine disk diffusion reports both organisms as susceptible to enrofloxacin and to amoxicillin-clavulanate, and the Pseudomonas is reported susceptible to gentamicin. The dog has been on oral amoxicillin-clavulanate for 3 weeks with no improvement. The owner asks why the 'susceptible' drugs are not working.
1. Explain the limitations of routine susceptibility testing in this chronic biofilm wound and why clinical failure can occur despite 'susceptible' results.
Read the worked answer
Routine disk diffusion and MIC testing are performed on planktonic (free-floating) organisms under standardized laboratory conditions. They predict activity against planktonic bacteria but do not account for the wound environment.
Reasons for clinical failure despite susceptibility:
- Biofilm: bacteria in biofilms are phenotypically tolerant-reduced metabolic activity, poor drug penetration through the matrix, and persister cells-so MICs from planktonic testing overestimate efficacy.
- Polymicrobial synergy: P. aeruginosa and S. pseudintermedius coexist; one may shield the other, and interspecies interactions alter drug response.
- Poor tissue penetration: chronic wounds have impaired perfusion, necrosis, and exudate that reduce local drug concentrations below the MIC.
- Inoculum effect and resistance emergence: high bacterial loads and beta-lactamase production can inactivate drugs locally.
- Compliance and dosing: 3 weeks of oral therapy without source control (debridement) is inadequate.
- Sampling: a deep tissue sample is better than a swab, but the cultured organisms may not represent the biofilm community.
Judgement: susceptibility results are necessary but not sufficient; source control and biofilm disruption are the rate-limiting steps.
2. Outline a management plan and explain what additional laboratory information would be most useful.
Read the worked answer
Management plan:
- Source control: surgical or sharp debridement of necrotic tissue and biofilm, frequent wound lavage, and appropriate dressings. This is the single most important intervention.
- Antimicrobial stewardship: reassess whether systemic antimicrobials are needed; if used, base choice on culture and susceptibility, but recognize that topical therapy (e.g., an appropriate antiseptic) may be more effective for biofilm than oral drugs.
- Recheck culture after debridement: the flora may change; avoid repeated empirical courses.
- Address underlying causes: foreign material, poor perfusion, or immunosuppression.
Additional laboratory information that would help:
- MIC values rather than categorical results, to guide dosing and detect borderline susceptibility.
- Biofilm-oriented testing (e.g., minimum biofilm eradication concentration) if available, though not standard.
- Beta-lactamase and resistance gene detection for P. aeruginosa and S. pseudintermedius (e.g., mecA) to anticipate resistance.
- Repeat deep tissue culture after debridement to confirm the dominant organisms.
Judgement: the 'susceptible' label is not wrong-it is answering a different question than the clinician is asking. The plan must prioritize debridement and reassessment over simply switching antibiotics.